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Abstract
Background: Plantar pressures are commonly used as clinical measures, especially to determine optimum foot
orthotic design. In rheumatoid arthritis (RA) high plantar foot pressures have been linked to metatarsophalangeal
(MTP) joint radiological erosion scores. However, the sensitivity of foot pressure measurement to soft tissue
pathology within the foot is unknown. The aim of this study was to observe plantar foot pressures and forefoot
soft tissue pathology in patients who have RA.
Methods: A total of 114 patients with established RA (1987 ACR criteria) and 50 healthy volunteers were assessed
at baseline. All RA participants returned for reassessment at twelve months. Interface foot-shoe plantar pressures
were recorded using an F-Scan
® system. The presence of forefoot soft tissue pathology was assessed using a
DIASUS musculoskeletal ultrasound (US) system. Chi-square analyses and independent t-tests were used to
determine statistical differences between baseline and twelve months. Pearson’s correlation coefficient was used to
determine interrelationships between soft tissue pathology and foot pressures.
Results: At baseline, RA patients had a significantly higher peak foot pressures compared to healthy participants
and peak pressures were located in the medial aspect of the forefoot in both groups. In contrast, RA participants
had US detectable soft tissue pathology in the lateral aspect of the forefoot. Analysis of person specific data
suggests that there are considerable variations over time with more than half the RA cohort having unstable
presence of US detectable forefoot soft tissue pathology. Findings also indicated that, over time, changes in US
detectable soft tissue pathology are out of phase with changes in foot-shoe interface pressures both temporally
and spatially.
Conclusions: We found that US detectable forefoot soft tissue pathology may be unrelated to peak forefoot
pressures and suggest that patients with RA may biomechanically adapt to soft tissue forefoot pathology. In
addition, we have observed that, in patients with RA, interface foot-shoe pressures and the presence of US
detectable forefoot pathology may vary substantially over time. This has implications for clinical strategies that aim
to offload peak plantar pressures.
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Patients with rheumatoid arthritis (RA) present with
pain, changes in gait, foot deformity and restrictions in
the choice of footwear [1-4]. This has led to the devel-
opment of guidelines for the assessment and manage-
ment of foot complications associated with RA. Annual
foot health screening is recommended with the aim of
identifying changes in foot health and monitoring foot
health interventions [5,6]. However, in a recent study of
patients with RA we demonstrated that a high percen-
tage of soft tissue pathology within the forefoot detect-
able by musculoskeletal ultrasound (US) was often
missed by clinical examination [7]. In addition, we
found that US detectable soft tissue pathology within
the forefoot was clinically relevant but varied in preva-
lence over time and hypothesised that this was not
necessarily due to RA disease but potentially associated
with mechanical factors [8].
Measurement of foot-shoe interface pressures is
increasingly used in clinical practice to determine clini-
cal interventions, such as foot orthoses, for patients with
RA, yet there is very little evidence for this practice over
time. In cross-sectional studies peak plantar pressures
are most often reported and evidence shows the forefoot
as the region with the highest peak plantar pressures
[9-14]. Notably, the clinical relations of plantar pressures
in RA patients are less well understood. Some have
attempted to address this using radiographic erosion
scores that show associations of MTP joint erosions
with peak plantar foot pressures [11,13,15]. A main criti-
cism of the radiological erosion scores is that they only
give information on prevalent joint damage and are
insensitive to RA soft tissue changes [16,17]. We there-
fore decided to investigate patterns of foot-shoe inter-
face pressures and presence of US detectable soft tissue
pathology in a cohort of RA participants at two time
points, baseline and twelve months.
Methods
The optimal research design was considered to be a
longitudinal cohort study in which the foot pathology
and foot pressure characteristics of a heterogenous
group of patients who have RA were assessed at two
time points. The use of two cross sectional time points
within the same population allows for better under-
standing of the effect of variability in pathophysiology of
RA within the foot over time. Embedded within the
design of study was a case reference study, to enable
comparisons of baseline demographic and clinical char-
acteristics of the RA study sample with healthy control
participants.
Approval for the study was obtained from the South-
ampton and South West Hampshire research ethics
committee for the RA participants and the Faculty of
Medicine, Health and Life Sciences, University of South-
ampton Research ethics committee for the healthy parti-
cipants. All participants gave informed written consent
prior to participation.
Study population
The study population consisted of a consecutive sample
of 114 RA patients who attended the Rheumatology
Department at Southampton General Hospital. Data col-
lection took place in the Wellcome Trust Clinical
Research Facility, Southampton General Hospital,
between August 2006 and December 2008. These indivi-
duals were participants in the RA Feet Ultrasound pro-
ject (FeeTURA), a prospective cohort study designed to
investigate the epidemiology of forefoot pathology in RA
patients. The point of entry into FeeTURA included all
patients who have RA who were attending for routine
rheumatological clinical care during the recruitment
period (April 2006 - April 2007). Previous publications
have described the high prevalence of forefoot bursal
hypertrophy in this patient group [7,8]. The present ana-
lysis was conducted to examine foot pressure outcomes
in a subgroup of the FeeTURA project participants.
To be eligible for participation in the parent FeeTURA
study, participants had to be over the age of eighteen
and have a positive diagnosis of RA as defined by the
previous American College of Rheumatology (ACR)
1987 criteria [18]. Patients were excluded from the
study if they had a history of previous forefoot surgery,
received a corticosteroid injection to the forefoot within
the three months prior to this study, had an additional
musculoskeletal disease (e.g. primary osteoarthritis, gout,
Paget’s, systemic lupus erythematosus), or had a serious
medical (other than RA) or psychological disorder that
would prevent completion of the study protocol. Also,
for this foot pressure study, individuals who could not
walk five metres were excluded.
A total of 149 patients were recruited into the parent
FeeTURA study and assessed at baseline (start of the
study). The number dropped to 120 who were re-
assessed at twelve months due to non-responses (n =
21), death (n = 1), illness (n = 6) and non-eligibility
based on an inability to walk five metres (n = 1). During
the pre-selection process for this investigation, data
from a further 6 subjects that were mal-recorded at
either baseline or twelve months were excluded from
the final analyses.
A gender matched healthy comparison group was
recruited from the students and staff of the University
of Southampton and assessed at the start of the study at
baseline only. The inclusion criteria were an age of 18 +
years, no positive diagnosis of an inflammatory arthro-
pathy and all participants had to fulfill the same exclu-
sion criteria as those for the RA group. Fifty healthy
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range 19-61; mean weight 74 kg, range 54.5-120) were
recruited and plantar pressure measurements and ultra-
sound data subsequently recorded. Participants were
instructed to attend the visit wearing comfortable flat
shoes that they wore the most at the time.
Assessment of demographic and clinical characteristics of
the RA participants
Demographic data including age, gender, weight, height,
disease duration and presence of rheumatoid factor was
recorded. Information regarding current medication
including Disease Modifying Anti-Rheumatic Drug
(DMARD) use was obtained from the patients’ clinical
notes. C-reactive protein (CRP) and Erythrocyte Sedimen-
tation Rate (ESR) values were obtained from the clinical/
laboratory database. Clinical activity of RA disease was
assessed by the disease activity score 28 tender and swol-
len joint count (DAS28-ESR) [19] and was obtained from
the patients’ clinical notes within one month of the visit.
All foot assessments were conducted by a single investi-
gator (CB) at both time points and followed recommended
guidelines for clinical assessment [5,6]. This included
observation of the presence of foot deformities: hallux
abducto valgus (HAV), 5
th metatarsophalangeal (MTP)
joint exostosis, lesser toe deformity, MTP joint subluxa-
tion, pes cavus and pes planus. Motion at the ankle, sub-
talar, mid-tarsal and first MTP joints were assessed and
classified as full motion, limited motion or rigid according
to clinical guidelines [5,6]. Information regarding use of
foot orthotic devices, presence of foot ulceration and
access to clinical foot services was also recorded.
Footwear was assessed and categorised as either pre-
scribed therapeutic footwear or retail (shop bought)
footwear. Footwear was further noted as being suitable
or not suitable according to fit and style (e.g. court
styles and high heel/stiletto shoes were deemed unsuita-
ble). Due to the high numbers of participants and the
highly emotive factors associated with both prescribed
therapeutic and retail footwear [4,20,21] it was neither
economically feasible nor clinically desirable to standar-
dise footwear between visits. Participants were
instructed to attend each visit wearing comfortable flat
shoes that they wore the most at the time.
Both subscales of the Leeds Foot Impact Scale Ques-
tionnaire (LFIS), impairment/footwear (LFISIF)a n d
activity limitation/participation restriction (LFISAP)p r e -
viously validated for use in RA populations [22] were
used to identify patient reported foot impact. LFISIF
contains twenty one items related to foot pain and joint
stiffness, as well as footwear related impairments with a
total score range 0 -21. LFISAP contains thirty items
related to activity limitation and participation restriction
with a total score range 0-30 [22]. Responses to each
question are dichotomized as yes or no and scoring is a
simple tally for each domain [22] with 4 or less sug-
gested to represent good foot health and scores higher
than 4 representing poor foot health [23].
Foot pressure measurement
A portable pressure measurement device, the FScan
® in-
shoe system, (Tekscan Inc. USA) was used to record
foot-shoe interface pressures. The FScan
® system has
recently been demonstrated as highly reliable and suita-
ble for measurement of plantar foot pressures in RA
patients in clinical practice [24]. The system is calibrated
to weight and uses Force Sensing Resistor (FSR) tech-
nology to enable dynamic, real time measurement to
measure the interface between the foot and footwear.
The instrumented insole is composed of 960 Sensing
Elements/Foot (Sensels), each 0.15 mm in thickness
with a density of four sensors per cm
2. It was trimmed
to fit footwear so that it did not interfere with either
walking, comfort or fit of footwear (FScan
® system fea-
tures, Tekscan US).
A predetermined walkway of approximately five metres
was established along the length of the clinical room. Each
participant was initially asked to walk the length of the
walkway to familiarise themselves with the protocol and
become accustomed to the cables. All participants were
asked to walk with their own footwear in a straight line at
a comfortable walking speed, away from the FScan
® sys-
tem so that any cable trip hazard was avoided. An identical
standard recommended protocol was followed for each
participant to minimise variations in recordings.
The data acquisition parameters were prescribed to
record 10 seconds of information with a 165Hz sam-
pling frequency. The FScan
® system automatically
records the individual data from all of the sensors and
estimates the pressure distribution on the plantar aspect
of the feet during each footstep, storing data on the sys-
tem for later analysis.
F-Scan
® sensors are marketed as re-useable and pre-
vious laboratory work has identified sensor life-spans of
40 trials over ten metres [25]. However, we are aware of
reported limitations of the FScan
® pressure measure-
ment system employed, especially the reliability of the
sensors has been questioned [9,26]. Therefore, we con-
ducted a repeated measures same subject study to test
reliability of the sensors for clinical use. Our findings
suggested that there was a trend in the loss of FScan
®
sensor lifespan following multiple clinical uses after 20
trials. To minimise the variation and inaccuracy of data
recordings we adopted a strict protocol as follows:
i. The sensors were placed within the participants’
footwear with the backing intact to minimise
damage as recommended [25].
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ticipant code, number of ‘walks’and number of steps
taken was noted on the sensor log sheet.
iii. Sensors were discarded after maximum use of 20
times (over five metres) or if physical damage to the
sensor was observed.
iv. In addition, with careful recalibration of sensors
at each trial and observation of the walking trials,
any mal-recordings were identified and excluded
from the final data analysis.
The FScan
® system was set to automatically discard
the first and last footsteps. The third footstep was
selected for analysis as this was considered representa-
tive of mid-gait and peak pressures were calculated.
Using the FScan
® standard masking software, the foot-
prints were divided into six segments, A (lateral-fore-
foot, ie. 3
rd to 5
th MTP joints), B (medial-forefoot, ie.1
st
to 2
nd MTP joints), C (lateral-midfoot), D (medial-mid-
foot), E (lateral-rearfoot), F (medial-rearfoot). The loca-
tion (ie. segment A, B, C, D, E or F) was noted in which
the peak pressure of the footstep was identified.
To determine relations in locations of US detectable
forefoot pathology and location of peak pressure, cases
in which the peak pressure was displayed within the
forefoot as either medially dominant (segment B) or lat-
erally dominant (segment A) were selected for analysis.
Ultrasound assessments
All US scans were performed immediately after the clin-
ical foot examinations and foot pressure measurements
by a single investigator (CB). We attempted to reduce
the effect of investigator bias by maintaining a systema-
tic order to the data collection and using experienced
independent data handlers to double enter and clean all
the information onto the data sheet.
A Diasus ultrasound system (Dynamic Imaging Ltd,
UK) was used to image the forefoot of both feet to
determine the presence of forefoot pathology (MTP
joint synovial hypertrophy and erosion and plantar fore-
foot bursal hypertrophy). The Diasus ultrasound system
(Dynamic Imaging Ltd. Scotland UK) operates as a sys-
tem with dual probe of which we employed the 8-16
MHz, footprint 26 mm, for dorsal scans and the 5-12
MHz linear probe, footprint 40 mm, for plantar scans.
Scanning was in B-Mode and recorded according to
standard guidelines for MTP joint pathology [27] and
previous recommendations for detection of plantar fore-
foot bursal hypertrophy [28]. Good image acquisition
and interpretation agreement (kappa 0.702; p < 0.01)
with an expert US radiologist was confirmed prior to
data collection [28].
The presence or absence of MTP joint synovial hyper-
trophy and erosion was recorded in the first to fifth
MTP Joints. The presence or absence of forefoot bursal
hypertrophy was recorded in the intermetatarsal (IM)
spaces 1/2, 2/3, 3/4, 4/5 and the sub-metatarsal (SM)
head areas 1 - 5. Locations of forefoot pathology were
allocated as A (lateral-forefoot, ie. 3
rd to 5
th MTP joints
including IM spaces 3/4 and 4/5, SM areas 3,4,5) or B
(medial-forefoot, ie.1
st to 2
nd MTP joints, including IM
spaces 1/2 and 2/3, SM areas 1,2) (Figure 1).
To facilitate analysis for associations, the scores for US
detectable pathology presence were summated as
follows:
Segment A (Lateral): presence of MTP joint synovial
hypertrophy 3, 4 and 5 + presence of MTP joint erosion
3, 4 and 5 + presence of forefoot bursal hypertrophy IM
3/4, 4/5, SM 3, 4, 5. Segment B (Medial): presence of
MTP joint synovial hypertrophy 1, 2 + presence of MTP
joint erosion 1, 2 + presence of forefoot bursal hypertro-
phy IM 1/2, 2/3, SM 1, 2.
Analysis
Using prior data [10] for normally distributed matched
pairs with peak pressure as the primary outcome, power
calculations indicated that the sample size of 114 for
90% power was more than adequate to detect differ-
ences in outcomes of pathology and peak plantar pres-
sures. All data analyses were conducted using Statistical
Package for the Social Sciences (SPSS) version 17.0 soft-
ware (SPSS, Chicago IL). Unless otherwise noted, a p
value of less than 0.05 was considered the critical level
to determine statistical significance.
The analyses mainly focused on descriptive changes in
the presence and location of US detectable forefoot
pathology and value and location of peak pressure at
baseline for both RA and healthy participants and after
a period of twelve months for RA participants only.
Demographic and clinical characteristic information is
presented as mean and standard deviations (+/-SD). The
Figure 1 Diagramatic representation of the division of the
forefoot into medial and lateral pathology. Legend: M =
metatarsal head; IM = intermetatarsal space; SM = sub-metatarsal
area.
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presented as frequencies of occurrence and graphically
as bar charts. Chi-square (c
2)a n a l y s e sw e r eu s e dt o
determine differences within location of peak pressures
between RA and healthy participants at baseline and for
RA participants with location of peak pressures and
location of forefoot pathology from baseline to 12
months. Chi-square (c
2) analyses were also used to
determine differences in peak pressure values and loca-
tions according to footwear type of the RA participants
at baseline and twelve months.
Independent sample t-tests were used to determine
differences between peak pressure values for RA and
control participants and paired t-tests were used to
determine differences for peak pressure values for the
RA participants from baseline to twelve months. Change
in the demographic and clinical variables was calculated
as person specific data and is presented as frequencies.
Pearson’s correlation coefficient was used to determine
interrelationships between the US detectable pathology
and values of peak pressure within each forefoot seg-
ment at baseline and at 12 months, as well as between
the changes in forefoot pathology and changes in peak
pressure values after 12 months. The distribution of
data for both peak pressures and US detectable forefoot
pathology were found to be approximately normal, justi-
fying the use of a parametric method for assessing
correlation.
Results
RA participant demographics
One hundred and fourteen patients (93 female and 21
male; 22 seronegative, 89 seropositive, 3 missing data)
were included the study. The mean age of the RA parti-
cipants was 59.6 years (SD:12.0; range: 25-87) and mean
disease duration was 11.8 years (SD: 10.3; range 0.6-43)
at baseline start of the study. The group of RA partici-
pants were heterogeneous as can be seen by the clinical
and demographic variables for baseline and twelve
months (Table 1). Analysis of group means showed no
significant change over the 12 month period for all vari-
ables. However when person specific data was calculated
it is notable that change had taken place over the twelve
month period with almost equal numbers of participants
increasing as decreasing for each variable.
Pharmacological treatment appeared to be stable
within the group. At baseline the participants’ regular
treatment of RA included 66% (n = 75) taking metho-
trexate and 47% (n = 53) taking anti-TNFa (Adalimu-
mab, Infliximab, Etanercept) therapy. At 12 months the
participants’ regular treatment of RA included 71% (n =
81) taking methotrexate and 46% (n = 52) taking anti-
TNFa (Adalimumab, Infliximab, Etanercept) therapy.
RA participant clinical foot characteristics
Patient reported foot impact appears high with mean
impairment/footwear scores of 10.6/21 (baseline) and
10.3/21 (twelve months) and mean activity limitation/
participation restriction 16.5/30 (baseline) and 16.6/30
(twelve months) (Table 1). Analysis of person specific
data shows that both scores changed over the twelve
month period with almost equal numbers of participants
experiencing an increase in foot impact as those experi-
encing a decrease (Table 1).
A high percentage of symmetrical foot deformity was
observed for HAV, 5
th MTP joint exostoses, lesser toe
deformities, MTP joints 1-5 subluxation and pes plano
valgus foot position at both baseline and 12 months
(Figure 2). From Figure 3, the highest proportion of par-
ticipants had limited ranges of motion in their foot
joints at both time points.
At baseline 56% (n = 64) had recorded foot symptoms
in their clinical notes, 61% (n = 70) had seen a chiropo-
dist or podiatrist but only 31% (n = 35) were currently
receiving clinical foot care on a regular basis. No partici-
pants had recorded presence of foot ulceration although
7% (n = 8) reported a previous history of foot ulceration.
Access to clinical foot care appeared to have improved
Table 1 Demographic and clinical characteristics of the RA participants at baseline and 12 months (N = 114).
Baseline
Mean (± SD)
12 months
Mean (± SD)
Raw Change
Mean (± SD)
PSC
Up
PSC
Down
PSC
No Change
Weight (kg) 73.3 (15.5) 73.2 (15.4) - 0.1 (4.3) 56 (49%) 57 (50%) 1 (1%)
Wellbeing (VAS) 40.1 (23.8) 36.2 (22.8) - 3.3 (25.8) 56 (49%) 56 (49%) 2 (2%)
ESR (mm/hour) 22.9 (18.6) 24.6 (20.3) 1.8 (16.9) *47 (41%) 53 (47%) 6 (5%)
CRP (mg/litre) 12.4 (19.5) 14.8 (25.0) 2.9 (29.1) *50 (44%) 39 (34%) 12 (10%)
DAS-28 3.9 (1.3) 4.1 (1.4) 0.2 (1.8) *35 (31%) 25 (22%) 17 (15%)
LFISIF (x/21) 10.6 (4.9) 10.3 (4.8) - 0.4 (3.3) 44 (39%) 53 (47%) 17 (15%)
LFISAP (x/30) 16.5 (9.5) 16.6 (9.7) - 0.1 (5.7) *53 (47%) 43 (38%) 17 (15%)
Key:*ESR 8 missing data; CRP 13 missing data; DAS-28 37 missing data; LFISAP 1 missing data.
Legend: PSC = person specific change n(%); VAS = visual analog score; ESR = Erythrocyte sedimentation rate; CRP = C-reactive proteins; DAS-28 = 28 joint
disease activity score; LFISIF = Leeds Foot Impact Score, impairment/footwear subscale; LFISAP = Leeds Foot Impact Score, activity participation limitation subscale.
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cal foot care on a regular basis. Foot ulceration was
noted in 2% (n = 2) at twelve months.
At baseline 97% (n = 111) wore retail shoes and 3% (n
= 3) wore prescribed therapeutic shoes. Of the retail
shoes, 16% (n = 18) were deemed unsuitable by the
podiatrist. At 12 months 93% (n = 106) wore retail
shoes and 6% (n = 7) wore prescribed therapeutic shoes.
Of the retail shoes, 6% (n = 7) were deemed unsuitable
by the podiatrist. At baseline 11% (n = 12) wore simple
insoles, 4% (n = 5) wore moulded insole devices and 3%
(n = 3) wore total contact foot orthoses. Slightly more
wore simple insoles (15%, n = 17), moulded insole
devices (6%, n = 7) and total contact foot orthoses (4%,
n = 5) at twelve months.
Foot pressure characteristics (RA participants and healthy
controls)
Peak pressure values within the whole footstep were sig-
nificantly different at baseline between the RA partici-
pants and the group of healthy control participants
(Table 2). To assess whether these differences could be
due to the confounding influences of age and weight, an
analysis of variance (ANOVA) was performed. After
adjustment for age and weight the results remained sig-
nificant (p < 0.001).
No significant differences were found in peak pressure
values for the RA participants from baseline to 12
months (Table 3). However when person specific data
was calculated it is notable that change had taken place
over the twelve month period with almost equal num-
bers of participants having an increase (left 47%, right
47%) in peak foot pressure as those who had a decrease
(left 53%, right 54%).
Once the footprint was segmented into the six compo-
nents, the majority of RA participants displayed peak
pressure values within the forefoot region (ie. segments
A and B) in both feet (Table 4 Figure 4). At baseline no
significant differences were found in the locations of the
peak pressures between the RA participants and the
group of healthy control participants (left c
2 = 0.185, df =
1, p = 0.185 or right feet c
2 = 0.004, df = 1, p = 0.947).
When the locations of peak pressures were analysed
for the RA participants at baseline and twelve months
Figure 2 Clinical foot characteristics of the RA participants at baseline and 12 months.
Figure 3 Foot joint characteristics of the RA participants at baseline and 12 months.
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2 =
12.063, df = 1, p = 0.001) and right feet (c
2 =4 . 6 2 7 ,d f
= 1, p = 0.031). Further analysis of person specific data
showed that peak pressure location was stable in only
6 1 %( n=6 9 )o fp a r t i c i p a n t si nt h er i g h tf o o ta n do n l y
34% (n = 39) in the left foot (Table 5). This suggests
that, in RA patients, whilst the location of peak foot
pressures is predominantly within the medial aspect of
the forefoot, this may change over time.
US detectable forefoot pathology (RA participants)
Frequency of the presence of US detectable forefoot
pathology was high. When categorized as medial (seg-
ment B) or lateral (segment A), the presence of MTP
joint erosions appeared to be predominantly lateral.
MTP joint synovial hypertrophy appeared to be predo-
minantly lateral at baseline, but was different at twelve
months being predominantly medial. Plantar forefoot
bursal hypertrophy has been reported previously in the
parent FeeTURA study [7,8] and in this sub analysis was
also predominantly lateral at both baseline and twelve
months (Table 6).
When person specific changes were analysed, MTP
joint erosion accounted for the least change in status
and location and thus the most stable pathology whilst
just under half of participants were observed to have a
stable status and location of MTP joint synovial hyper-
trophy and forefoot bursal hypertrophy (Table 7). This
suggests that the pattern of presence of MTP joint syno-
vial hypertrophy and forefoot bursal hypertrophy within
the forefoot is variable in over half our participants.
Correlations of US detectable forefoot pathology and
peak forefoot pressure values
Following the trend observations, the data was explored
further to determine any significant associations
between the presence of US detectable pathology and
peak pressure values in each of the forefoot segments.
Findings showed that there was a significant negative
correlation between the presence of US detectable
pathology and peak pressure values in the right foot lat-
eral segment at follow up (PCC = -0.412, p = 0.046), but
this only demonstrates borderline significance at the 5%
level, and care should be taken when inferring from this
level of evidence. No other significant associations were
found in any of the other variables. The data was
explored further to determine any significant associa-
tions between the changes of US detectable pathology
and changes in peak pressure values. No other signifi-
cant associations were detected.
Discussion
This investigation is considered the first to identify the
presence of soft tissue pathology within the forefoot
using US and patterns of foot-shoe interface pressures
in a large cohort of patients with RA at two time points.
Primarily we have observed that peak plantar pressures
measured at the foot-shoe interface, are most likely to
occur in the medial aspect of the forefoot (confirmed at
both time points). By contrast, US detectable soft tissue
pathology, forefoot bursal hypertrophy (confirmed at
both time points) and MTP joint synovial hypertrophy
(confirmed at twelve months) are most likely to be pre-
sent in the lateral aspect of the forefoot. Additionally,
we have observed that in this patient group the location
of US detectable forefoot soft tissue pathology and loca-
tion of peak foot-shoe interface pressures vary substan-
tially over time.
O u rf i n d i n g sa r et h u si m p o r t a n ta si ti so u ro b s e r v a -
tion that, in clinical practice, the assessment of foot-
shoe interface pressures for patients who have RA is
increasing. In this patient group, clinical strategies to
Table 2 Foot pressure characteristics of the RA participants compared to the control group at baseline.
RA
Mean (SD)
Control
Mean (SD)
Students t-test
(95% CIs)
Left peak pressure (kPa)* 559.1 (281.6) 460.9 (146.0) t = 2.330, p = 0.021
(14.96-181.45)
Right peak pressure (kPa)* 581.5 (298.0) 449.5 (167.8) t = 2.931, p = 0.004
(43.0-220.9)
Key: *Denotes significance at p < 0.05
Table 3 Foot pressure characteristics of the RA participants at baseline and 12 months.
Baseline
Mean (SD)
12 months
Mean (SD)
Students t-test
(95% CIs)
PSC
increase
PSC
decrease
Left peak pressure (kPa) 559.1 (281.6) 565.1 (291.3) t = -0.180, p = 0.857
(-72.6-60.5)
54 (47%) 60 (53%)
Right peak pressure (kPa) 581.5 (298.0) 582.3 (396.7) t = -0.020, p = 0.984
(-84.7-83.0)
53 (47%) 61 (54%)
Legend: PSC = person specific change n(%)
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additional information, such as US imaging to prevent
overloading of potential current soft tissue inflammation
that may not be detected clinically [7,29,30].
Previously in RA participants peak plantar pressures
have been investigated against radiological erosion
scores. In a small group (N = 16) of RA participants
with established disease (mean 13.0 years) significant
associations between erosion scores in the lateral MTP
joints (3
rd to 5
th) and peak pressure under 3
rd to 5
th
MTP joints were reported [15]. Others categorised RA
participants with established disease, but in remission,
(N = 50), into high and low forefoot erosion scores and
found significantly higher forefoot peak pressures occur-
ring in the high erosion group [11]. The latter authors
also reported that the highest pressure values were
under the 5
th MTP joint [11]. Interestingly, in a larger
group (N = 62) of RA participants, with established dis-
ease (mean 8 years) and high frequency of foot symp-
toms (89%), significant associations were found between
erosion scores and peak pressures at MTP joints 1 and
4 [13]. It is however difficult to directly compare these
results with our findings as each investigation used bare-
foot pedobarographic systems to record foot pressures,
used different erosion scores and all were cross
sectional.
The presence of forefoot erosion is indicative of preva-
lent foot disease and in the present study erosions were
predominantly evident within the lateral aspect of the
forefoot. It was also found that half of our participants
had stable unchanging MTP joint synovial hypertrophy
and forefoot bursal hypertrophy. By contrast, for half of
the cohort we found that the presence in status of MTP
joint synovial hypertrophy and forefoot bursal hypertro-
phy varied substantially over the twelve month period.
We have previously hypothesised that this indicates the
formation and regression of soft tissue pathology within
the forefoot is a dynamic process that may be related to
biomechanical adaptation [8].
Otter et al. [10] proposed that high plantar pressures
observed in RA participants may be associated with a
pain avoidance strategy related to off-loading the main
Table 4 Location of forefoot pressures in the RA
participants(n (%)) at baseline and twelve months.
Forefoot Midfoot Rearfoot
Lateral
A
Medial
B
Lateral
C
Medial
D
Lateral
E
Medial
F
Baseline
Left 37
(33%)
63
(55%)
0 0 2 (2%) 12
(10%)
Right 20
(18%)
70
(61%)
2 (2%) 1 (1%) 5 (4%) 16
(14%)
Twelve
Months
Left 37
(33%)
56
(49%)
1 (1%) 0 7 (6%) 13
(11%)
Right 24
(21%)
72
(63%)
1 (1%) 0 4 (4%) 13
(11%)
Figure 4 The most common pattern of foot pressure seen in
one RA participant’s left foot pressure-map. Legend: LA = left
lateral forefoot segment; LB = left medial forefoot segment; LC =
left midfoot lateral segment; LD = left medial midfoot segment; LE
= left lateral rearfoot segment; LF = left medial rearfoot segment.
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Page 8 of 11site of inflammatory pain such as MTP joint synovial
hypertrophy. In this study analysis, we found no differ-
ence in the location of peak plantar pressures between
the RA and healthy participants although our results
indicate that RA participants have significantly higher
values of peak plantar pressures than healthy partici-
pants. The latter findings concur with those of other
investigators [13,14,31]. Our evidence that, over time,
changes in US detectable soft tissue pathology appear to
be out of phase with changes in foot-shoe interface
pressures both temporally and spatially does support the
suggestion that these patients biomechanically adapt
t h e i rg a i ta w a yf r o mf o r e f o o tp a t h o l o g y .H o w e v e r ,w e
only found a negative association between the presence
of US detectable pathology and peak pressure values in
the right foot, lateral segment, at follow up which only
demonstrated borderline significance. We also have to
consider that peak pressures may not be the most clini-
cally useful variable to focus on in this patient popula-
tion. Further prospective research utilising investigation
of other foot pressure variables, such as duration of
peak pressure, pressure-time integrals and centre of
pressure relative to forefoot soft tissue pathology and
patient reported foot symptoms would be useful to
determine optimal clinical assessment protocols.
It is inevitable that the heterogenous nature of the RA
cohort in this study leads to the complexity of changes
associated with foot status. Indeed the DAS-28 scores
over the twelve month period indicate a high level of
active disease within the cohort, although treatment
appears stable. It was notable that disease status, mea-
s u r e db yE S R ,C R P ,w e l l - b e i n ga n dD A S - 2 8 ,w a sa l s o
substantially variable over the 12 months. These findings
are consistent with the well documented variability of
RA disease over time [32-34].
Given the temporal variability of RA disease over time it
is surprising that there is a lack of longitudinal data related
to measurement of plantar foot pressures in RA. Mostly
what is known is attributable to cross-sectional analytical
data [10,13,24,35]. There is even less available evidence
that investigates foot-shoe interface pressures over time
with most attempts at longitudinal investigation in this
population using barefoot pedobarographic assessment
[12,13,15]. A possible explanation is that measurement of
foot-shoe interface pressures is highly dependent on the
shoe condition and therefore tight control over confound-
ing factors such as footwear and activity is required for
interventional studies. Inherent in this however is a dis-
connect in previous research findings and clinical utility of
in-shoe foot pressure measurement within the RA popula-
tion. The OMERACT (Outcome Measures in Rheumatol-
ogy) framework incorporates truth, discrimination and
feasibility as a filter to aid decisions as to the applicability
of measures [36]. The literature on plantar foot pressure
measurement in RA suggests that the methods may be fea-
sible [2] however, their ability to discriminate in clinical
practice has yet to be determined. Our aim was therefore
to examine the forefoot pathology of patients who had RA
at two cross sectional time points relevant to their usual
daily activities/habits to mimic routine clinical practice
assessments. It was not feasible to control for footwear
over such a long period of time and in such a large popu-
lation, which may be controversial.
As a response to this we performed additional analyses
and an analysis of variance to assess the confounding
influences of footwear. We found that the location of peak
foot pressure remained predominantly medial in all foot-
wear types. However, at twelve months, for the left foot
only, those wearing unsuitable shoes had higher peak pres-
sure values. In this study therefore, it is possible that for
the twelve month left foot data peak pressures for the
whole group may be inflated.
There are several strengths within this study that
include a longitudinal cohort follow up design, the large
sample size, and that it was a pragmatic clinical study
representative of secondary care in the UK. A few
Table 5 The presence of person specific(n) stable peak
pressure location over 12 months for the RA participants.
Peak pressure location Left Right
Stable presence lateral A 21 7
Stable presence medial B 13 54
Stable presence C,D,E,F 5 8
Total stable peak pressure 39 69
Percentage of cohort 34% 61%
Table 6 Location of forefoot pathology in the RA
participants(n (%)) at baseline and twelve months.
Pathology Lateral
dominance
Medial
dominance
Equally
distributed
No
pathology
Baseline
SynHy Left 37 (33%) 19 (17%) 15 (13%) 43 (38%)
Right 31 (27%) 25 (22%) 10 (9%) 48 (42%)
Erosion Left 94 (83%) 1 (1%) 6 (5%) 11 (10%)
Right 88 (77%) 2 (2%) 6 (5%) 18 (16%)
BurHy Left 58 (51%) 18 (16%) 20 (18%) 18 (16%)
Right 56 (49%) 13 (11%) 27 (24%) 18 (16%)
Twelve Months
SynHy Left 15 (13%) 34 (30%) 7 (6%) 58 (51%)
Right 19 (17%) 26 (23%) 14 (12%) 55 (48%)
Erosion Left 96 (84%) 1 (1%) 11 (10%) 5 (4%)
Right 89 (78%) 1 (1%) 14 (12%) 10 (9%)
BurHy Left 61 (54%) 7(6%) 32 (28%) 14 (12%)
Right 63 (55%) 14 (12%) 22 (19%) 15 (13%)
Legend: SynHy: MTP joint synovial hypertrophy; BurHy: Forefoot bursal
hypertrophy.
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Page 9 of 11potential limitations should also be considered. Primarily
our sample of participants was heterogenous, with estab-
lished disease and treated within secondary care and
thus may not be generalizable to all patients with RA.
Another potential limitation within this study is that we
did not include tenosynovitis within our US observa-
tions of the forefoot and were unable to delineate the
soft tissue structures in detail. Arguably this approach
may underestimate the presence of soft tissue pathology
within the forefoot. Such a limitation may be rectified
using Magnetic Resonance Imaging to delineate the soft
tissue structures.
Finally, for pragmatic analysis we categorised the forefoot
nominally into either medial or lateral segments and also
amalgamated the foot pathology data due to low counts in
these categories, thus caution is required in interpreting
this observational data. No further statistical inferences
could be made from this current analysis and we recom-
mend that future work in this area would be of value, parti-
cularly in the use of US detectable foot pathology and
interface foot-shoe pressure pattern identification and clus-
ter analysis [37]. Ideally, future work could focus on
whether it is the impact of discrete pathology, such as IM
or SM bursal hypertrophy, MTP joint synovial hypertrophy
or tenosynovitis that may be associated with high plantar
forefoot pressures or whether there is an ‘optimal level’ of
forefoot pathology that impacts on plantar foot pressures.
Conclusion
We have observed that there are considerable variations in
the presence and location of US detectable soft tissue fore-
foot pathology and patterns of foot-shoe interface pres-
sures over time in a large cohort of participants who have
RA. We also noted that, in patients with RA, the changes
in US detectable soft tissue forefoot pathology may be out
of phase with the location and values of peak interface
foot-shoe pressures. This implies that, in this patient
group, clinical strategies to offload observed peak pres-
sures, measured at the foot-shoe interface, over time may
require additional information, such as US imaging to pre-
vent overloading of existent soft tissue inflammation.
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